Qlife to develop SARS-CoV-2 total antibody test
Qlife has decided to initiate development of a Covid-19 antibody lgG/lgM test for the Egoo system.The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months. Thereafter, the project will be transferred to in-house specialists for integration to the Egoo device, analytical data collection and product optimization. Qlife expects to be able to CE mark for professional use late 2020 and submit a file for CE mark home use during the first quarter 2021. “With a relatively limited investment we can complement our